Vidofludimus calcium against Covid and other Viruses

[Dude]

Frankfurt University Hospital tests Vidofludimus calcium (IMU-838) for long covid. Recruitment has not yet started, probably in 2024. At the same time, a new faster test procedure is being trailed (RAPID).
The active ingredient vidofludimus calcium slows down the metabolism in activated T and B cells (which dampens the immune reaction), but hardly influences other immune cells. IMU-838 was previously in development for relapsing-remitting multiple sclerosis and other autoimmune diseases.


Vidofludimus calcium (IMU-838) - MoA
Dihydroorotate dehydrogenase (DHODH) inhibitor → inhibits synthesis of the nucleotide pyrimidine →

• Blockade of intracellular viral replication → broad efficacy against various viruses SARS-CoV-2, EBV, CMV and others
• Inhibition of lymphocyte activation → Reduction of the release of cytokines (messengers of inflammation) → Anti-inflammatory activity

At 33:00 (German Only)
Source: https://vimeo.com/873993707/description

 

[SWAlexander]

Dude: Thanks​

 

[Dude]

There is now a product page, with a lot more information. Could certainly be interesting for ME/CFS.

https://imux.com/pipeline/imu-838/

A targeted effect on hyperactive immune cells without suppression of normal immune function.

DHODH is a key enzyme in the metabolism of overactive immune cells and virus-infected cells. This mechanism is associated with the anti-inflammatory and anti-viral effects of vidofludimus calcium. By inhibiting DHODH, a key enzyme of pyrimidine de novo biosynthesis, highly metabolically active T and B immune cells experience metabolic stress, which leads to a modulation of their activity and function.

DHODH inhibition also leads to a direct anti-viral effect, which has been observed in various virus infected cells, such as EBV infections, hepatitis C virus infections, SARS-CoV-2 infections, cytomegalovirus infections and even hemorrhagic fever-causing viruses, such as Arena virus infections.

 

[Dude]

The long-awaited study with the drug Vidofludimus-Calcium is starting. The study begins in Frankfurt, with additional centers joining later on.

For more information on participation, please visit the following link.

https://www.netzwerk-universitaetsmedizin.de/projekte/napkon-tip/studie-rapid-revive

 

[SWAlexander]

Vidofludimus-Calcium

Thank you. There is extensive literature on Vidofludimus-Calcium, and I believe that Ulm is conducting trials as well. My friend, who has a preliminary diagnosis of ALS despite inconclusive test results and negative MRI findings, receives weekly calls encouraging him to participate.